Where neutral protease is permitted, and what the file must show
Neutral protease from Bacillus subtilis is regulated as a food enzyme preparation. A compliance review has to answer four questions that are often confused: may the preparation be used in this market, does the lot meet the purity limits, how is it described, and what may the brand claim? Each answer depends on the market and on the production strain.
Use, purity, labelling and claims are separate questions, and a compliance file has to answer all four for the destination market.
Four questions, four answers
The first question is permitted use: is this enzyme allowed in the intended food process? The second is purity: does the lot stay inside the contaminant and microbiological limits? The third is description: how is the preparation named on the label, including its carrier? The fourth is the claim: what may the brand say about the finished product?
“Neutral protease” is an activity, bacillolysin (EC 3.4.24.28), not a single authorised substance. Permission attaches to a preparation — organism, strain, fermentation medium and carrier included. Two powders can both read 50,000 U/g and still sit under different regulatory positions, which is why the file describes the preparation rather than only the activity.
European Union: national rules while the list is pending
Regulation (EC) No 1332/2008 is the framework. The regulation makes Union-list entry a condition of marketing or food use, and that list is still outstanding at the time of writing. The transitional position leaves national provisions on placing on the market and use in force in the Member States. Name the Member State of sale in the file, not only “the EU”, and check the current text before launch.
Applications sit on a Commission register; the file should identify the entry for this enzyme and this use. EFSA assesses the production strain and the process, not the activity name in the abstract. A 2024 opinion on a preparation with bacillolysin and subtilisin activities from a non-genetically modified Bacillus amyloliquefaciens strain, covering nine food processes, shows how closely the assessment is tied to the strain; a different preparation needs its own entry and evidence.
“EU approved” is not an accurate description while the list is pending. The defensible wording names the national provision, the register entry and the application status.
United States: the 21 CFR 184.1150 route
The US regulation that fits this preparation is 21 CFR 184.1150. It describes a bacterially-derived protease enzyme preparation made by pure-culture fermentation of a nonpathogenic and nontoxigenic strain of Bacillus subtilis or B. amyloliquefaciens, containing subtilisin (EC 3.4.21.62) and neutral proteinase (EC 3.4.24.28), and affirms it as GRAS for hydrolysing proteins and polypeptides under current good manufacturing practice. The section also points to the Food Chemicals Codex monograph on enzyme preparations and requires the absence of antibiotic activity by a validated method.
That is a food-use basis, not a supplement approval. A supplement brand still needs a dietary-ingredient basis under DSHEA and cGMP under 21 CFR 111, and the label and claims are separate questions. The brand should check that its intended use fits the basis instead of assuming that a food-enzyme citation covers every supplement format.
United Kingdom: check GB and NI separately
In Great Britain the assimilated version of Regulation (EC) No 1332/2008 applies. The Food Standards Agency and Food Standards Scotland hold the register of regulated-product authorisations, and the position should be checked for the specific enzyme, strain and use. Northern Ireland follows the EU regime, so a GB check does not answer the NI question. As in the EU, the current text governs, not a supplier's summary.
Limits and where they come from
| Parameter | Catalog limit | Market note |
|---|---|---|
| Lead | ≤3 mg/kg | EU supplements: 3.0 mg/kg on the product as sold |
| Arsenic | ≤2 mg/kg | No general EU limit for this matrix; the catalog sets 2 mg/kg |
| Cadmium | ≤1 mg/kg | EU supplements: 1.0 mg/kg as sold |
| Mercury | ≤0.1 mg/kg | EU supplements: 0.10 mg/kg as sold |
| Microbiology | APC ≤10,000 cfu/g; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent | General food-safety obligation; customer specifications can be stricter |
| Loss on drying | ≤8.0% | Quality parameter; it also sets the activity basis |
Regulation (EU) 2023/915 sets the EU ceilings on the supplement as sold, not on the enzyme powder. The ingredient limit must be chosen so the finished product stays below the ceiling; that calculation belongs to the brand, and the COA is one input to it. US state rules and UK requirements can be tighter than the catalog, so the destination limit has to be checked rather than assumed.
The claim is the brand's document
This material carries no disease-related claim, and these pages cover the specification and the file rather than any effect in the body. “Neutral protease activity ≥50,000 U/g” is a specification statement, not a health claim.
Anything said about the finished product belongs to the brand and must satisfy the rules of the market where it is sold: the EU health-claims regulation, the US supplement framework and the retained UK regime each apply their own test. The enzyme file can support identity, activity and purity. It cannot support a statement about what the finished product does, and the label artwork should keep that line visible.
What ships with the lot
- Specification naming the unit and the assay conditions.
- Lot COA with result and limit in separate columns.
- TDS covering activity, solubility, pH and the pack format.
- Safety data sheet, including dust-control and exposure sections.
- Allergen declaration: source organism and carrier.
- Statement on GMO status for the organism and its inputs.
- Origin record and strain declaration.
- Composition statement, including the carrier.
- Stability data summary, grade- and pack-specific.
- Residual-solvent statement for the recovery process.
Checks before release to a market
| Check | Evidence |
|---|---|
| Market and process named | Memo covering the intended use, not only the substance |
| Organism and strain recorded | Origin file and strain declaration |
| Regulatory status confirmed | EU register entry, a 21 CFR 184.1150 or GRAS basis, or the UK register position |
| Contaminants inside the destination limit | Lot COA, plus a third-party report where needed |
| Carrier and allergen checked | Composition statement and label artwork |
| Pack wording checked | Activity, unit, carrier and storage on the label |
| Claims reviewed | Substantiation file held by the brand |
| Document pack complete | The ten items above, matched to the lot |
The catalog entry is on the neutral protease product page; release lines are on the COA page, source and activity evidence on the identity page, and the frameworks are summarised in the EU, US and UK notes. The quality page describes the release workflow.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation